You searched for cnsp - Page 9 of 23

CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) Anchors Focus and Priority on Berubicin Clinical Development for GBM Treatment

On September 30, 2022, CNS Pharmaceuticals (NASDAQ: CNSP), a clinical-stage biotechnology company specializing in the development of novel treatments with a focus on brain cancer, Glioblastoma Multiforme (“GBM”), and neuro-oncology, released its financial results for the third quarter of the 2022 financial year (“Q3 2022”). While making the announcement, John Climaco, CNS’s CEO, lauded the … Continue reading “CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) Anchors Focus and Priority on Berubicin Clinical Development for GBM Treatment”

The most common primary brain cancer in adults and one of the most aggressive, glioblastoma, remains a critical unmet medical need because of its level of morbidity and the lack of effective treatment options nearly a century after it was defined by pioneering neurosurgeons Percival Bailey and Harvey Cushing in 1926. Glioblastoma, known simply as … Continue reading “CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) Has Potential to Make History in Battle Against Deadly Brain Cancer with Berubicin”

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, has released data from its ongoing trial evaluating Berubicin for the treatment of recurrent glioblastoma multiforme (“GBM”). The data was presented at the annual meeting for the Society for Neuro-Oncology. Those … Continue reading “QualityStocksNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Releases Preliminary Results from Berubicin Trial”

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced that its Chief Executive Officer John Climaco will participate in the Virtual Investor “Ask the CEO” event. The live, moderated event is intended to provide the investment … Continue reading “QualityStocksNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) to Participate in ‘Ask the CEO’ Event”

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, announced the pricing of a public offering. The offering is comprised of 1,889,764 shares of common stock (or prefunded warrants in lieu thereof) along with warrants to purchase up … Continue reading “QualityStocksNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Releases Pricing for Public Offering”

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, has announced a 1-for-30 reverse split of its common stock. According to the announcement, the split was effective at 4:01 p.m. ET on Nov. 28, 2022. Starting today, CNSP common stock … Continue reading “QualityStocksNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) 1-for-30 Reverse Stock Split Now in Place”

Innovative brain tumor therapy developer CNS Pharmaceuticals (NASDAQ: CNSP) is reporting continued expansion of the number of clinical site launches for its evaluation of the company’s lead product candidate for treating recurrent glioblastoma multiforme (“GBM”). CNS Pharmaceuticals noted in a recent update about its anti-cancer drug candidates and its third quarter financial results that the … Continue reading “European Clinical Trial Site Expansion for CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) Brain Cancer Drug Candidate Drives Patient Enrollment”

CNS Pharmaceuticals (NASDAQ: CNSP) is an oncology drug development company specializing in developing anti-cancer drugs for the treatment of primary and metastatic brain and central nervous system cancer. “The first half of fiscal 2022 saw the company make a number of clinical and operational advancements in its pursuit of treatment for glioblastoma multiforme (‘GBM’), according … Continue reading “QualityStocksNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Seeking to Solve Unmet Need for GBM Treatment”

The National Brain Tumor Society anticipates that more than 13,000 Americans will receive a GBM diagnosis during 2022, accounting for 49.1% of all primary malignant brain tumors CNS announced the first patient in Europe has been enrolled and dosed in the global trial to evaluate Berubicin for the treatment of GBM Berubicin is a novel … Continue reading “CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) Announces First European Dosing in Potentially Pivotal GBM Trial”

CNS Pharmaceuticals CEO John Climaco participated in 5K run on November 5, to show support for brain tumor patients worldwide and help raise funds for research The company recently announced European clinical trial site activations for its potentially pivotal global trial evaluating Berubicin for the treatment of recurring glioblastoma multiforme The pivotal trial will study … Continue reading “CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) CEO Participated in The American Brain Tumor Association’s Breakthrough for Brain Tumors(R) 5K Run Following European Clinical Trial Site Activations”